Pulse Biosciences (PLSE) Scheduled to Post Earnings on Monday

Pulse Biosciences (NASDAQ:PLSE) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 12th. Individual that wish to register for the company’s earnings conference call can do so using this link.

Pulse Biosciences Stock Up 3.6 %

Shares of NASDAQ:PLSE opened at $15.65 on Friday. The stock’s 50 day moving average is $14.01 and its 200-day moving average is $10.63. Pulse Biosciences has a twelve month low of $3.78 and a twelve month high of $20.44. The firm has a market capitalization of $958.09 million, a price-to-earnings ratio of -19.32 and a beta of 1.75.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Tuesday, August 6th.

Insider Buying and Selling at Pulse Biosciences

In related news, CEO Burke Thomas Barrett purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average price of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at approximately $85,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 71.50% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.